Applying a "precision medicine" approach to drug development requires integrating a range of information in order to facilitate more informed decision making related to target selection and a greater understanding of the pharmacological aspects of the drug such as bioavailability, pharmacodynamics (PD), and pharmacokinetics (PK) (1) (2) (3) . Rational dose selection and clinical trial design are critical factors in development of therapeutic. Success is dependent upon robust PD biomarkers and constructing PK/PD models bridging animal and human testing. The first-in-human (FIH) dose selection traditionally relies on the No Adverse Effect Level (NOAEL) identified from preclinical toxicity studies, in order to identify a safe starting dose and a dose escalation scheme that allows rapid achievement of therapeutic levels in patients (4, 5) . Although this approach has been successfully utilized for small molecules with nonspecific dose-limiting toxicities, it may not be the optimal approach for biologics.
In the development of biologically-based therapeutic agents, the measurement of the binding of the biotherapeutic to its cellular target, receptor occupancy (RO), has become a critical component of the biomarker portfolio. RO analysis can contribute to establishing Minimal Biological Effect Level (MABEL) for a biotherapeutic agent and to establish optimal dosing and administration schedules. In addition, data generated in RO assays can be used to assess safety. Long-term maximum RO may be a hallmark of overdosing, or long-term binding which may lead to severe side effects and even toxicity (6) (7) (8) (9) (10) (11) .
Although measurement of ligand/receptor interactions can be conducted by western blotting or by administering radiolabeled test compound and detection, these methods can be limited by the cell numbers that can be analyzed, large data files, systems which are low throughput, the extra precautions required to work with radioactive compounds and the stability of the radiolabel. Since RO assays are most often applied it the evaluation of therapies directed at immune conditions and in targeted oncology therapy (2, 6, (12) (13) (14) (15) , flow cytometry is a technology that is well suited for performing these types of measurements. This methodology is widely used from research and development through clinical trials and has the ability to measure individual targets/receptors using fluorescent tags in specific cell populations.
RO ASSAY APPROACHES
RO assays range in complexity from simple (measuring the number of cell surface receptors bound by an antireceptor biotherapeutic agent), to highly complex (measuring receptor internalization or shedding). Data outputs include relative frequency (percent positive or absolute counts), or expression levels expressed as the fluorescence intensity or molecules of equivalent soluble fluorochrome (MESF). RO assays measure unbound or free receptors, total available receptors, and/or the proportion of bound receptors (Table 1) .
Free Receptor
Indirect determination of free receptors that are not occupied by biotherapeutic agent is performed using either a competitive antibody, or by use of fluorescently (17) labeled biotherapeutic agent. By definition, a competitive antibody will directly compete for binding of the same epitope as the biotherapeutic agent, meaning that the receptors detected will be free of biotherapeutic agent and thus allow binding of the competitive antibody. Use of a fluorescently labeled version of the biotherapeutic agent, often employed with monoclonalbased therapeutics, similarly binds to those receptors free of biotherapeutic agent ( Fig. 1 ). An example of this type of assay is the ACT-1 assay utilizing a monoclonal antibody with the same binding epitope as vedolizumab to detect free (unbound) sites on a4b7 integrin (16) . Careful reagent design and a good understanding or target/antigen kinetics is critical for the effectiveness of free receptor determination assays ( Table 2) . One of the main challenges to this approach is that if the affinity of the competitive antibody is lower or equal to the drug, it will measure free RO; but if it is higher, it may measure total (17) . Another challenge that can arise with assessment of free receptor is the presence of interfering factors which could neutralize the detection reagent and cause underestimation of free receptor. To overcome this challenge, one might use a molecule that does not have sequence homology with the drug molecule but competes with the drug for receptor binding.
Total Receptor
In contrast to free receptor determination, the detection of the Total Receptors available biotherapeutic involves the use of noncompetitive antibodies to detect all the expressed receptor targets, whether the biotherapeutic agent is present or not. This means that the noncompetitive antibody must bind to a different epitope on the receptor from that of the one recognized by the biotherapeutic agent. The use of free and total receptor determination in combination with one another can be used to determine the ratio of free (unoccupied) sites to total sites available as an assessment of achieved saturation (Fig. 2 ). An example of this type of assay has been described with IL-7Ra detected using labeled CD127 mAb that does not compete for binding with Ab1 to the receptor whether Ab1 is bound or not (18) .
Another approach to determine total receptor is to perform an incubation step in vitro in which all (28) receptors are saturated with biotherapeutic agent, and then the biotherapeutic agent is detected, similar to detection of bound receptor, with an antidrug (drug specific) antibody. Total available binding sites for the biotherapeutic agent in each patient may also be determined by using a super saturating amount of biotherapeutic agent. In this assay design, cells from the patient before treatment are incubated with saturating amounts of biotherapeutic agent in vitro and the bound biotherapeutic agent detected with antidrug antibody. Post-treatment samples are then tested at desired time points with the antidrug antibody both with and without pre-incubation using saturating amounts of biotherapeutic agent.
Bound Receptor
Direct assessment of bound biotherapeutic agent may be especially useful in determining true RO. In order to detect bound receptors, a fluorescently labeled antidrug antibody is most often used. The biotherapeutic agent bound to the target receptors is then detected with the antidrug antibody (Fig. 3) . If drug is a monoclonal antibody, a detection antibody (i.e. anti-human F c or anti id, etc.) that does not competitively inhibit the drug-target binding may be used as drug detection reagent. An example of this type of assay has been described with the detection of VX15/2503, a human IgG4 specific for SEMA4D with an IgG4-specific monoclonal (19) .
Receptor Modulation
Receptor modulation assays assess binding of a biotherapeutic agent to its target receptor by monitoring the effect on the modulation of the target receptor or some other functional effect due to biotherapeutic agent binding. As an example, biotherapeutic agent binding may inhibit internalization of the receptor in response to an external modulating challenge and therefore allow for detection of bound receptors by receptor specific antibodies. The degree of receptor expression detected is relatively proportional to the amount of biotherapeutic agent bound to those receptors (Fig. 4) . Green et al. have shown example data of the measurement of CCR5 expression before and after modulation challenge in the absence and presence of drug during course of dosing (17) . If receptor modulation occurs before sample analysis, including but not limited to internalization, shedding, capping, etc., precautions need to be taken during sample collection/processing, shipping temperature, and time (based on sample stability data) to minimize such an effect. Figure 1 to include total receptors available, recognized by a noncompetitive antibody bound to a different epitope on the receptor from the one recognized by the biotherapeutic agent. This design can be used determine the ratio of free (unoccupied) sites to total sites available.
FIG. 2. Illustration of free and total receptor assay design expands on

RECEPTOR OCCUPANCY ASSAYS BY FLOW CYTOMETRY IN DRUG DEVELOPMENT
IMPLEMENTATION
RO assays add value to each stage of the life cycle of a biotherapeutic agent. Early on, RO assays assist in compound screening and to demonstrate target engagement in disease models, providing information on the relationship of target engagement to efficacy (29) (30) (31) (32) (33) (34) (35) (36) (37) . Additionally, as with many PD assays, RO assays may be used preclinically to help model the starting dose to be used in human subjects in early Phase 1 clinical studies (29) .
During Phase 1 clinical testing, RO studies are often used to demonstrate that the same target binding observed in the animal models holds true in humans (14, 31, 35, (38) (39) (40) (41) (42) . It is important to demonstrate that an RO assay which has been developed in preclinical models still performs as expected in humans. Due to factors such as species differences in receptor density levels, speciesspecific ligands, RO assays typically require further optimization when moving from the animal models to humans.
During Phase 2 clinical testing, RO assays are used to define the relationship between the concentration of the biotherapeutic, receptor binding, and early efficacy signals (15, 43) . A comparison of RO and efficacy measurements will assist in determining the efficacious dosing range and inform Go/No Go decision making.
In Phase 3 programs RO analysis can be used to help define the population PK characteristics of the biotherapeutic agent. Age, weight, and gender may be examined, along with RO, to determine if there is any impact of these covariates on the biotherapeutic agent mechanism of action (10) . RO assays may be performed on a limited number of subjects to ensure that the receptor is saturated to the desired level. Finally, after approval in the desired indication RO assays can be used as comparators for new indications, or the next generation compounds.
IMPACT OF RECEPTOR OCCUPANCY ASSAYS
An example of the potential impact of RO can be found in the severe adverse events, in the form of a cytokine storm, that were observed in a FIH clinical trial of TGN1412, anti-CD28 super-agonist (32, 44) . TGN1412 was known to bind non-human primate CD28 suggesting that the cynomolgous monkey model would be relevant in determine starting doses for the FIH trial. The NOAEL dose from the cynomolgous monkey was predicted using the established guidelines to determine a safe starting dose for the FIH trial. At the time this was the procedure to control any adverse toxicological effects (e.g. off-target effects seen with small molecule drugs). However, due to fundamental biologic and pharmacologic differences in monkeys and humans for the TGN1412 target and its downstream effects, the NOAEL dose obtained from monkeys was too high, and did not account for the biologic differences. The consequence was that the FIH dose at 0.1 mg/kg was 20-to 30-fold too high; resulting in life-threatening cytokine release syndrome in the healthy volunteers (32, 39, 44, 45) . As a result, new guidance from the European Medicines Agency (EMA) (46) recommends selecting a starting dose that would result in a Minimum Anticipated Biologic Effect Level (MABEL) (46) for products in which a potential risk had been identified. The MABEL calculation is based on a dose-response curve of drug effect and a PK/PD model can be constructed to describe a quantitative relationship between drug exposure and RO. RO is commonly used as a PD biomarker, especially for cell-surface targeting therapy. Incorporation of RO results from animal studies into the PK/PD model refines the model and enables prediction of RO for human dose selection. While this may not directly reflect an efficacious concentration, it demonstrates the drug concentration below which the likelihood of efficacy is low.
The review of the data from the preclinical studies of TGN1412 suggested a number of pharmacological assessments that could have been used to determine the MABEL (45) . The use of RO estimations to determine PD effects indicated that the administered starting dose of 0.1 mg/kg in the FIH trial for TGN1412 led to >90% predicted RO, whereas the MABEL dose was predicted to lead to a 10% RO (32, 39, 44) . The TGN1412 case highlights the importance of correctly predicting the MABEL, where reliable PK/PD modeling and the use of RO assessments are fundamental tools. With new understanding of the biology and the pharmacology in association to the TGN1412 target new trials are now being conducted (47) .
CONCLUSIONS
Several methods for performing these assays have been presented, to demonstrate the variety of approaches available. It should be noted; however, that assay planning, development and validation must be performed to determine which method is best suited to the biotherapeutic agent being monitored (36) to demonstrate the variety of approaches available. When running a receptor occupancy assay in the context of a clinical trial, data must be able to be compared in a longitudinal manner. In this case, day to day variability must be taken into account. Since not just frequency of target cell populations is assessed, but also fluorescence output of labelled reagents, steps should be taken to normalize this flow cytometric measurement. For example, beads can be used to establish target ranges which are used to set up the cytometer before running the RO assay; in this way comparability in data collected over time can be ensured.
